In vivo validation of metastasis-regulating microRNA-766 in human triple-negative breast cancer cells.
10.5625/lar.2017.33.3.256
- Author:
Keunhee OH
1
;
Dong Sup LEE
Author Information
1. Laboratory of Immunology/Cancer Biology, Department of Biomedical Sciences, Seoul National University College of Medicine, 103 Daehakro, Jongno-gu, Seoul, Korea. dlee5522@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Human triple-negative breast cancer;
microRNA;
metastasis
- MeSH:
Breast Neoplasms;
Cause of Death;
Cell Proliferation;
Drug Therapy;
Female;
Heterografts;
Humans*;
Lung;
MicroRNAs;
Neoplasm Metastasis;
Recurrence;
Triple Negative Breast Neoplasms*
- From:Laboratory Animal Research
2017;33(3):256-263
- CountryRepublic of Korea
- Language:English
-
Abstract:
Breast cancer is the second most common cancer and the most frequent cancer in women worldwide. Recent improvements in early detection and effective adjuvant chemotherapies have improved the survival of breast cancer patients. Even with initial disease remission, one-third of all breast cancer patients will relapse with distant metastasis. Breast cancer metastasis is largely an incurable disease and the main cause of death among breast cancer patients. Cancer metastasis is comprised of complex processes that are usually not controllable by intervention of a single molecular target. As a single microRNA (miRNA) can affect the aggressiveness of breast cancer cells by concurrently modulating multiple pathway effectors, a metastasis-regulating miRNA would represent a good disease target candidate. In this study, we evaluated the functional capacity of a newly defined human metastasis-related miRNA, miR-766, which was previously identified by comparing a patient-derived xenograft primary tumor model and a metastasis model. Compared to vector-transfected control cells, miR-766-overexpressed triple-negative breast cancer cells exhibited similar primary tumor growth in the orthotopic xenograft model. In contrast, tumor sphere formation and Matrigel invasion were significantly decreased in miR-766-overexpressed breast cancer cells compared with control cancer cells. In addition, lung metastasis was dramatically reduced in miR-766-overexpressed breast cancer cells compared with control cells. Thus, miR-766 affected the distant metastasis process to a greater extent than cancer cell proliferation and primary tumor growth, and may represent a future therapeutic target to effectively control fatal breast cancer metastasis.
